When a Single Drug Class Becomes Too Big to Ignore
Something strange started happening in 2024, and most of us didn’t notice. Semaglutide—the active ingredient in Ozempic and Wegovy—became the best-selling pharmaceutical in history by annual revenue growth, hauling in over 21 billion dollars globally. That’s not a minor pharmaceutical success story. That’s a signal that how we think about metabolic disease, obesity, and their downstream consequences just got fundamentally disrupted.
But here’s what nobody warned us about: when a drug becomes this dominant, this fast, it doesn’t just treat one disease in isolation. It creates a cascade. It forces researchers to ask uncomfortable questions. It destabilizes clinical trial designs. It redefines what we even mean by “indication” when a single molecule starts showing meaningful effects across addiction neurobiology, cardiovascular pathology, and now—most intriguingly—neurodegenerative disease.
I’ve been reading through the emerging literature at 2 and 3 in the morning, and what I’m seeing isn’t incremental progress. It’s the kind of scientific moment where the implications get bigger the longer you sit with them.
The Cardiovascular Win That Changed Everything
Let’s start with what we know for certain. The SELECT trial follow-up published in the New England Journal of Medicine in 2025 demonstrated that semaglutide reduced cardiovascular events by 20 percent in non-diabetic obese patients. This matters because it decoupled weight loss from diabetes prevention. For decades, we’ve treated obesity as a harbinger of diabetes, and diabetes as the real threat to your heart. The SELECT results suggested something different: weight loss itself—or more precisely, the metabolic cascades triggered by GLP-1 receptor activation—appears to protect the cardiovascular system independent of diabetes status.
You can read the full results yourself in the SELECT Trial Results — New England Journal of Medicine, and I’d genuinely recommend it. The design is elegant. The numbers are solid. But what fascinates me is the second-order implication: if GLP-1 agonists protect against cardiovascular events in non-diabetic people, then we’ve identified a mechanism that has nothing to do with glucose control. The drug is doing something deeper in the vascular biology itself.
That realization opened the door to a question that nobody was asking in 2023: what else might this mechanism affect?
The Addiction Neurobiology Plot Twist
Here’s where things get genuinely wild. Researchers at the University of Southern California published a 2025 study examining GLP-1 receptor agonists in alcohol cravings. Three hundred participants. Controlled cohort. The result: a 40 percent reduction in alcohol cravings. Not in diabetics. Not in obese patients specifically. In people with alcohol use disorder.
This is where I had to step back and think about what we’re actually observing. GLP-1 receptors are distributed throughout the brain, particularly in regions associated with reward processing and motivation. When semaglutide and tirzepatide activate these receptors, they’re not just signaling in the hypothalamus to suppress appetite. They’re modulating dopamine pathways. They’re touching the neural circuits that encode craving itself.
The clinical implications are staggering and premature. We have a promising signal in a single well-designed trial. We do not yet have evidence that GLP-1 agonists should be prescribed for addiction treatment. But we have something more important: a reason to investigate whether an entire class of medications originally developed for weight loss might have applications in addiction psychiatry. That’s a research direction that could reshape how we approach substance use disorders in five to ten years.
And this is before we talk about Eli Lilly’s tirzepatide, which achieved up to 22.5 percent average body weight reduction in the SURMOUNT trials, exceeding any previously approved weight-loss medication. More potency means stronger receptor activation. Stronger receptor activation means we’re more likely to see off-target effects—and also more likely to discover genuinely novel therapeutic applications.
The Alzheimer’s Question We’re Only Now Beginning to Ask
This is the one that keeps me awake. The NIH launched the ATTAIN-AD trial in late 2025, specifically designed to investigate semaglutide’s effect on amyloid plaque accumulation in early Alzheimer’s patients. This isn’t a fishing expedition. This is a direct, hypothesis-driven investigation into whether a GLP-1 agonist might slow neurodegeneration.
Why would this even be plausible? Because obesity is a risk factor for Alzheimer’s disease. Because metabolic dysfunction correlates with amyloid pathology. Because GLP-1 receptors in the brain might be involved in microglial activation and neuroinflammation—speculative, yes, but mechanistically grounded. We’re talking about a plausible pathway, even if we don’t fully understand it yet. You can explore the broader research context at the NIH GLP-1 and Neurological Research Overview.
I want to be careful here: the ATTAIN-AD trial is preliminary. It’s a signal-seeking study. It could yield nothing. Mechanistic plausibility doesn’t guarantee clinical efficacy. But the fact that the NIH is investing resources into this question suggests that the scientific community has collectively noticed something worth investigating at scale.
This is the cascade effect in action. A drug becomes dominant for one indication. Researchers look closer. They notice the receptor distribution in the brain. They see suggestive data from addiction studies. They hypothesize about neuroinflammation. And suddenly, what began as a treatment for type 2 diabetes is being investigated as a potential Alzheimer’s intervention.
The Messier Reality of Drug Discovery in the Age of Big Data
What troubles and excites me in equal measure is that we’re now in a period where the traditional drug development pipeline is getting inverted. Historically, we identified a disease target, designed a molecule, ran trials, and waited for the indication to emerge. Now we have molecules with exceptional sales, institutional momentum, and commercial incentive to find every possible application. That’s not inherently problematic, but it does create perverse incentives. It can lead to overstated results. It can deprioritize unglamorous but rigorous negative findings.
The antidote is exactly what we’re seeing: peer-reviewed publication, trial registration, and public investment in validation studies like ATTAIN-AD. The SELECT trial was rigorous. The USC addiction study was well-designed. These aren’t speculative claims—they’re preliminary findings from solid science. But preliminary is the operative word. We need to sit with this uncertainty. We need to resist the urge to turn every positive signal into a medical breakthrough.
That said, I genuinely believe we’re in the early stages of understanding what GLP-1 agonists can do. The cardiovascular protection in non-diabetics alone justified the research attention. The addiction data suggests a novel therapeutic vector. The Alzheimer’s hypothesis is speculative but mechanistically grounded. These aren’t separate stories. They’re chapters in a larger narrative about how a single drug class can reshape our understanding of metabolic, psychiatric, and neurological disease.
What are you seeing in this data? Do you think the cascade of investigations into GLP-1 applications represents genuine scientific promise, or commercial momentum driving research agendas? I’d genuinely love to hear your thoughts on where this leads.